For the quarter ending 2026-03-31, SNSE had $143,657K increase in cash & cash equivalents over the period. -$10,739K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -170,236 | -4,717 | -4,568 | -11,800 |
| Stock-based compensation expense | 12,898 | 295 | 254 | 725 |
| Depreciation and amortization | 29 | 30 | 30 | 62 |
| Accretion on marketable securities | -83 | -115 | -142 | -442 |
| Impairment of financing right-of-use asset assets | - | 0 | - | - |
| Impairment of equipment | - | 0 | - | - |
| Non-cash lease expense | 381 | 374 | 366 | 770 |
| Amortization of financing lease right-of-use assets | 1 | 4 | 4 | 9 |
| Acquired in-process research and development from the acquisition of faeth therapeutics | -132,957 | - | - | - |
| Gain on asset disposal | 21 | - | -1 | -20 |
| Prepaid expenses | -10,744 | -266 | -331 | 354 |
| Other assets | -442 | -178 | 126 | -28 |
| Accounts payable and accrued liabilities | -104 | 77 | 269 | -113 |
| Compensation and employee benefits | 2,645 | 164 | 381 | -1,107 |
| Operating lease liabilities | -407 | -399 | -386 | -801 |
| Other liabilities | - | 0 | 0 | - |
| Net cash used in operating activities | -10,733 | -3,864 | -3,586 | -13,003 |
| Purchases of property and equipment | 6 | 0 | 0 | 16 |
| Purchases of short-term investments | 43,894 | 6,522 | 9,847 | 8,786 |
| Maturities of short-term investments | 6,000 | 8,603 | 11,590 | 24,500 |
| Proceeds from sale of property and equipment | 0 | 0 | 0 | 250 |
| Net cash assumed in the acquisition of faeth therapeutics | -6,464 | - | - | - |
| Net cash (used in) provided by investing activities | -31,436 | 2,081 | 1,743 | 15,948 |
| Principal payments for financing leases | 62 | 113 | 152 | 525 |
| Proceeds from issuance of series b redeemable convertible preferred stock | 200,000 | - | - | - |
| Proceeds from the sale of financing lease assets | - | 0 | 0 | 142 |
| Issuance costs from the private placement issuance of series b redeemable convertible preferred stock | 15,145 | - | - | - |
| Payment of employee restricted stock tax withholdings | 0 | 0 | 0 | 3 |
| Employee stock purchase plan proceeds | - | 0 | 0 | 5 |
| Cash in lieu of fractional shares for reverse stock split | - | 0 | 0 | 1 |
| Exercise of options into common stock | 1,033 | 2 | - | - |
| Net cash provided by (used in) financing activities | 185,826 | -111 | -152 | -382 |
| Net increase (decrease) in cash and cash equivalents | 143,657 | -1,894 | -1,995 | 2,563 |
| Cash and cash equivalents at beginning of period | 8,668 | 10,562 | 9,994 | - |
| Cash and cash equivalents at the end of period | 152,325 | 8,668 | 10,562 | - |
Sensei Biotherapeutics, Inc. (SNSE)
Sensei Biotherapeutics, Inc. (SNSE)